Warning! GuruFocus detected
1 Severe warning sign
with IKNA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Ikena Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US45175G1085
Compare
Compare
Traded in other countries / regions
IKNA.USA Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2021-03-26Description
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.54 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.3 | |||||
| 3-Year FCF Growth Rate | 24.5 | |||||
| 3-Year Book Growth Rate | -23.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.86 | |||||
| 9-Day RSI | 44.05 | |||||
| 14-Day RSI | 43.56 | |||||
| 3-1 Month Momentum % | -12.99 | |||||
| 6-1 Month Momentum % | -22.54 | |||||
| 12-1 Month Momentum % | -5.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.8 | |||||
| Quick Ratio | 11.8 | |||||
| Cash Ratio | 11.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -0.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -33.81 | |||||
| ROA % | -30.28 | |||||
| ROIC % | -327.86 | |||||
| 3-Year ROIIC % | 155.11 | |||||
| ROC (Joel Greenblatt) % | -948.86 | |||||
| ROCE % | -35.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.51 | |||||
| Price-to-Tangible-Book | 0.51 | |||||
| EV-to-EBIT | 0.97 | |||||
| EV-to-Forward-EBIT | -0.41 | |||||
| EV-to-EBITDA | 0.98 | |||||
| EV-to-Forward-EBITDA | -0.31 | |||||
| EV-to-Forward-Revenue | 0.96 | |||||
| EV-to-FCF | 1.16 | |||||
| Price-to-GF-Value | 13.2 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 103.09 | |||||
| FCF Yield % | -72.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IKNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ikena Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.01 | ||
| Beta | 0.53 | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 40.19 | ||
| 14-Day RSI | 43.56 | ||
| 14-Day ATR ($) | 0.069529 | ||
| 20-Day SMA ($) | 1.35 | ||
| 12-1 Month Momentum % | -5.63 | ||
| 52-Week Range ($) | 1.22 - 1.94 | ||
| Shares Outstanding (Mil) | 48.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ikena Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ikena Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ikena Oncology Inc Frequently Asked Questions
What is Ikena Oncology Inc(IKNA)'s stock price today?
The current price of IKNA is $1.32. The 52 week high of IKNA is $1.94 and 52 week low is $1.22.
When is next earnings date of Ikena Oncology Inc(IKNA)?
The next earnings date of Ikena Oncology Inc(IKNA) is 2025-05-13 Est..
Does Ikena Oncology Inc(IKNA) pay dividends? If so, how much?
Ikena Oncology Inc(IKNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers